September 14, 2014 | Israeli company Teva Pharmaceutical Industries published the results of a study that showed that its multiple sclerosis treatment Copaxone has less side effects with 40mg doses three days a week than 20mg doses once a day. According to Teva’s President of Global R&D and Chief Scientific Officer Dr. Michael Hayden, “We’re pleased these results provide supportive data that fewer injections with three-times-a-week Copaxone 40 mg resulted in half as many reported IRAEs (injection-related adverse side effects) compared to the number of IRAEs with the Copaxone 20 mg once-daily dosing regimen.” Teva was founded in 1901 by Eli Hurvitz and is based in Petah Tikvah, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

AI Startup Helps Doctors Analyze Heart Scans
February 08, 2023

AI Monitors High-Speed Conveyor Belts For Defects
February 08, 2023

Israel Hi-Tech Group In Rescue Mission To Turkey
February 08, 2023

Israeli Startup Tests Cancer Treatment With Pharma Giant
February 07, 2023
Facebook comments